The Canadian Drug Expert Committee (CDEC) and INESSS (Quebec) have recommended in favour of reimbursement of Galafold for….
Information on the Canadian Fabry Family Camp: May 29-31, 2020
Information regarding the upcoming webinar.
Information on the Avrobio study: AVRO-RD-01-201, Phase2 Gene Therapy Study
Please see below information on a new study, which is being performed at Emory University by Lacie Mehr, Dawn Laney, MS, CGC, and Morgan Simmons, MS, CGC. Living with FABRY disease? Interested in joining an exciting new study? We are seeking people of ALL AGES with a genetic diagnosis of Fabry disease to join a different […]
Hello Canadian Fabry Association! Please see this great video featuring Dr. Aneal Khan. It is a great story on Precision Medicine and Gene Sequencing . https://vimeo.com/healthandfamily/review/345778206/93e2d1f34d For any additional information please visit these resources: www.facebook.com/UpHealthandWellness/ www.facebook.com/CanadianHealthFamily/ https://twitter.com/CAHealthFamily
Hello CFA Members, please see below this information on AVROBIO’s ongoing study (AVR-RD-01). Thank you! AVROBIO, a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose. Gene therapy involves the transplantation of normal genes into cells in order to […]
On behalf of the Canadian Fabry Association we would like to thank Graham Crouse for serving as a board member for over 15 years. Graham was one of the original board members and has helped many patients in Nova Scotia to cope with Fabry disease. He has done an amazing job at facilitating our quarterly […]
Click here for the full article. Highlights: Relevant Background AVROBIO has two ongoing clinical studies of AVR-RD-01. AVR-RD-01 is an investigational gene therapy for Fabry disease. Eight patients have been dosed across these two studies. There are five patients in the investigator-sponsored Phase 1 trial, which is fully enrolled. There are three patients […]
Subscribe error, please review your email address.
CloseYou're now subscribed, thank you!
CloseThere was a problem with your submission. Please check the field(s) with red label below.
CloseYour message has been sent. We'll get back to you soon!
Close